JANX
Janux Therapeutics, Inc.
Biotechnology
Market Cap$878M
5Y Perf.-41.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
JANX vs RVMD
Revenue, margins, valuation, and 5-year total return — side by side.
RVMD
Revolution Medicines, Inc.
Biotechnology
Market Cap$30.30B
5Y Perf.+349.0%
JANX vs RVMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | JANX | RVMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $878M | $30.30B |
| Revenue (TTM) | $18M | $0.00 |
| Net Income (TTM) | $-158M | $-1.37B |
| Gross Margin | 47.2% | — |
| Operating Margin | -8.8% | — |
| Total Debt | $22M | $159M |
| Cash & Equiv. | $52M | $384M |
JANX vs RVMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
JANX
RVMD
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Janux Therapeutics,… (JANX) | 100 | 58.3 | -41.7% |
| Revolution Medicine… (RVMD) | 100 | 449.0 | +349.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JANX vs RVMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RVMD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Janux Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
JANX
Janux Therapeutics, Inc.
The Growth Play
JANX is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth -5.6%, EPS growth -43.0%, 3Y rev CAGR 5.1%
- Lower volatility, beta 1.45, Low D/E 2.3%, current ratio 39.04x
- -5.6% revenue growth vs RVMD's -98.6%
Best for: growth exposure and sleep-well-at-night
RVMD
Revolution Medicines, Inc.
The Income Pick
RVMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.08
- 393.1% 10Y total return vs JANX's -42.2%
- Beta 1.08, current ratio 7.14x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | JANX | -5.6% revenue growth vs RVMD's -98.6% |
| Quality / Margins | RVMD | 2.8% margin vs JANX's -8.8% |
| Stability / Safety | RVMD | Beta 1.08 vs JANX's 1.45 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RVMD | +278.4% vs JANX's -43.4% |
| Efficiency (ROA) | JANX | -15.7% ROA vs RVMD's -59.1%, ROIC -15.3% vs -54.3% |
JANX vs RVMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
JANX vs RVMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJANXLAGGINGRVMD
RVMDRevolution Medicines,…
2leads
JANXJanux Therapeutics, I…
2leads
6 Total Categories
CATEGORYLEADERvs RVMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
JANX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JANX7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RVMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
RVMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
JANX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
JANX and RVMD operate at a comparable scale, with $18M and $0 in trailing revenue.
| Metric | JANXJanux Therapeutic… | RVMDRevolution Medici… |
|---|---|---|
| RevenueTrailing 12 months | $18M | $0 |
| EBITDAEarnings before interest/tax | -$156M | -$1.4B |
| Net IncomeAfter-tax profit | -$158M | -$1.4B |
| Free Cash FlowCash after capex | $0 | -$1.1B |
| Gross MarginGross profit ÷ Revenue | +47.2% | — |
| Operating MarginEBIT ÷ Revenue | -8.8% | — |
| Net MarginNet income ÷ Revenue | -8.8% | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -41.7% | -102.7% |
JANX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — JANX and RVMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | JANXJanux Therapeutic… | RVMDRevolution Medici… |
|---|---|---|
| Market CapShares × price | $878M | $30.3B |
| Enterprise ValueMkt cap + debt − cash | $848M | $30.1B |
| Trailing P/EPrice ÷ TTM EPS | -7.95x | -23.95x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 87.80x | — |
| Price / BookPrice ÷ Book value/share | 0.94x | 16.61x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — JANX and RVMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
JANX leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
JANX delivers a -16.5% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-83 for RVMD. JANX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), JANX scores 2/9 vs RVMD's 1/9, reflecting mixed financial health.
| Metric | JANXJanux Therapeutic… | RVMDRevolution Medici… |
|---|---|---|
| ROE (TTM)Return on equity | -16.5% | -83.2% |
| ROA (TTM)Return on assets | -15.7% | -59.1% |
| ROICReturn on invested capital | -15.3% | -54.3% |
| ROCEReturn on capital employed | -15.6% | -53.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.02x | 0.10x |
| Net DebtTotal debt minus cash | -$30M | -$225M |
| Cash & Equiv.Liquid assets | $52M | $384M |
| Total DebtShort + long-term debt | $22M | $159M |
| Interest CoverageEBIT ÷ Interest expense | — | -81.62x |
JANX leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RVMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RVMD five years ago would be worth $48,210 today (with dividends reinvested), compared to $5,781 for JANX. Over the past 12 months, RVMD leads with a +278.4% total return vs JANX's -43.4%. The 3-year compound annual growth rate (CAGR) favors RVMD at 80.0% vs JANX's 2.0% — a key indicator of consistent wealth creation.
| Metric | JANXJanux Therapeutic… | RVMDRevolution Medici… |
|---|---|---|
| YTD ReturnYear-to-date | +6.5% | +80.3% |
| 1-Year ReturnPast 12 months | -43.4% | +278.4% |
| 3-Year ReturnCumulative with dividends | +6.1% | +483.1% |
| 5-Year ReturnCumulative with dividends | -42.2% | +382.1% |
| 10-Year ReturnCumulative with dividends | -42.2% | +393.1% |
| CAGR (3Y)Annualised 3-year return | +2.0% | +80.0% |
RVMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
RVMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RVMD is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than JANX's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 91.5% from its 52-week high vs JANX's 41.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | JANXJanux Therapeutic… | RVMDRevolution Medici… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.08x |
| 52-Week HighHighest price in past year | $35.34 | $155.70 |
| 52-Week LowLowest price in past year | $12.12 | $34.00 |
| % of 52W HighCurrent price vs 52-week peak | +41.1% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 49.8 | 66.4 |
| Avg Volume (50D)Average daily shares traded | 974K | 2.9M |
RVMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates JANX as "Buy" and RVMD as "Buy". Consensus price targets imply 95.3% upside for JANX (target: $28) vs 8.6% for RVMD (target: $155).
| Metric | JANXJanux Therapeutic… | RVMDRevolution Medici… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $28.40 | $154.80 |
| # AnalystsCovering analysts | 15 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
JANX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RVMD leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallJanux Therapeutics, Inc. (JANX)Leads 2 of 6 categories
Loading custom metrics...
JANX vs RVMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is JANX or RVMD a better buy right now?
Analysts rate Janux Therapeutics, Inc.
(JANX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — JANX or RVMD?
Over the past 5 years, Revolution Medicines, Inc.
(RVMD) delivered a total return of +382. 1%, compared to -42. 2% for Janux Therapeutics, Inc. (JANX). Over 10 years, the gap is even starker: RVMD returned +393. 1% versus JANX's -42. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — JANX or RVMD?
By beta (market sensitivity over 5 years), Revolution Medicines, Inc.
(RVMD) is the lower-risk stock at 1. 08β versus Janux Therapeutics, Inc. 's 1. 45β — meaning JANX is approximately 34% more volatile than RVMD relative to the S&P 500. On balance sheet safety, Janux Therapeutics, Inc. (JANX) carries a lower debt/equity ratio of 2% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — JANX or RVMD?
On earnings-per-share growth, the picture is similar: Janux Therapeutics, Inc.
grew EPS -43. 0% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — JANX or RVMD?
Revolution Medicines, Inc.
(RVMD) is the more profitable company, earning 0. 0% net margin versus -1576. 7% for Janux Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0. 0% versus -1576. 7% for JANX. At the gross margin level — before operating expenses — JANX leads at 47. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — JANX or RVMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is JANX or RVMD better for a retirement portfolio?
For long-horizon retirement investors, Revolution Medicines, Inc.
(RVMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), +393. 1% 10Y return). Both have compounded well over 10 years (RVMD: +393. 1%, JANX: -42. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between JANX and RVMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.